ovarian cancer

  • June 8, 2020  

    New Treatments for Ovarian Cancer in 2020

    Smruti Vidwans, PhD

    Women with ovarian cancer once relied solely on chemotherapy to treat their disease. However, in recent years, treatment options have expanded, and new options are also on the horizon. Read on to learn more about ovarian cancer and how it can be treated. What are the risk factors and symptoms of ovarian cancer? The American Cancer Society estimates that, in 2020, about 21,750 American… Read more »

  • May 30, 2020  

    Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020  

    Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study Bookmark

    George Lundberg, MD

    Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.

    Go to full paper published in the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 2, 2020  

    FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer Bookmark

    George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.

    Go to full article published by the FDA.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Ovarian Cancer: Is This the Beginning of the End? Bookmark

    George Lundberg, MD

    Article from Healio curated by Editor in Chief George Lundberg, MD, who notes: 

    This piece discusses recent insights into ovarian cancer, including the fact that this type of cancer sometimes originates in the fallopian tube, and that drugs known as PARP inhibitors show great therapeutic promise.

    Go to full article published by Healio.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Novel, High-Accuracy Blood Test Can Screen for Multiple Cancers Bookmark

    George Lundberg, MD

    Article from MDLinx curated by Editor in Chief George Lundberg, MD, who notes: 

    Very early detection of potentially lethal cancer remains an elusive goal. Blood tests that evaluate methylation of cell-free DNA may be one strategy for earlier detection of ovarian cancer and other types of cancer. High sensitivity and specificity are crucial.

    Go to full article published by MDLinx.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    FDA Approves Test for Late-line HRD+ Ovarian Cancer Bookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    A new diagnostic test and new therapeutic drugs have received approval from the U.S. Food and Drug Administration (FDA) for certain advanced ovarian cancers, which are always difficult to treat.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    Ovarian Cancer: Pathogenesis and Current Recommendations for Prophylactic Surgery Bookmark

    George Lundberg, MD

    Research paper from the Journal of the Turkish-German Gynecological Association curated by Editor in Chief George Lundberg, MD, who notes: 

    Since many ovarian cancers arise in the adjacent fallopian tube, 20-40% of ovarian cancer can be prevented by prophylactic salpingectomy.

    Go to full paper published in the Journal of the Turkish-German Gynecological Association.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 17, 2019  

    Ovarian Cancer—An Overview Bookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Ovarian cancer is particularly difficult; since early symptoms are few, it is often well-advanced before diagnosis. It kills more Americans than any other gynecologic malignancy. The cell types of origin vary greatly, as do treatment modalities. This multi-author 2019 review from Medscape includes established and experimental therapies.